HOME >> BIOLOGY >> NEWS
New roles for protein modifications in cell migration

lloprotease) protease, a family of secreted or membrane proteins first identified as components of various snake venoms, where they have hemorrhagic and anti-coagulatory effects. ADAM-family proteases have been implicated in a number of human physiological and pathological processes, including blood coagulation disorders, rheumatoid arthritis and asthma. These proteins act to proteolytically release membrane-bound growth factors or to disrupt components of extracellular matrices such as collagen and proteoglycans (which help to build skin and soft tissue), and their roles in development and differentiation are the focus of interest in many research labs.

Nishiwakifs team analyzed a number of mutations that result in aberrant gonadal phenotypes similar to those seen in mig-17 mutants, including the mutation of the gene that encodes MIG-23. This protein was found to be structurally related to nucleoside diphosphatases (NDPases), glycosylating proteins found in the Golgi apparatus, the intracellular processing center where proteins are modified, sorted and released from the cell. Glycosylation involves the addition of a sugar to a site on a protein chain, a post-translational modification whose roles are incompletely understood, but which is thought to serve a regulatory function in some signaling molecules. On further investigation, MIG-23 mutants showed reductions in NDPase activity. The wild-type MIG-23 protein successfully rescued yeast mutants for NDPase, lending solid support to the case for the NDPase nature of MIG-23.

The similarity between the MIG-23 and MIG-17 phenotypes suggested that the mutation of MIG-23 might result in abnormal MIG-17 glycosylation. Using gel electrophoresis, Nishiwaki and colleagues demonstrated that MIG-17 molecules in MIG-23 mutants had lower than normal molecular weights consistent with the loss of glycosylation, while immunoblotting studies confirmed that in these mutants MIG-17 failed to bind sugars at the normal l
'"/>

Contact: Doug Sipp
sipp@cdb.riken.jp
RIKEN Center for Developmental Biology
25-Dec-2003


Page: 1 2 3

Related biology news :

1. UT Southwestern scientists prove certain proteins play unexpected roles in genetic transcription
2. New molecular link key to cellular proteins involved in cancer progression, other diseases
3. Researchers identify protein promoting vascular tumor growth
4. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
5. Experimental drug shown to block mutant protein causing blood disease
6. Loss of the neuronal adhesion protein d-catenin leads to severe cognitive dysfunction
7. Images of tail of protein needed for cell multiplication suggest anticancer drug targets
8. New dye directly reveals activated proteins in living cells
9. Disruption of protein-folding causes neurodegeneration, mental retardation
10. A new protein is discovered to play a key role in cancer progression
11. Optimizing proteins death domain halts leukemia in laboratory study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New roles for protein modifications cell migration

(Date:8/6/2015)... 6, 2015  Today, U.S. Congressman Mike ... ™ to learn firsthand how Silicon Valley technologies ... is a world leader in multi-factor identity management ... helping federal agencies and commercial organizations achieve new ... "The vast majority of network breaches can ...
(Date:8/5/2015)... ALBANY, New York , August 5, 2015 /PRNewswire/ ... new market report titled "Facial Recognition Market - Global ... - 2022", the global market for facial recognition is ... market is driven by increased demand for surveillance systems ... to the rising number of crimes and terrorist activities ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... Phase I study of BHV-0223, a glutamate modulating ... regarding BHV-0223 and recently obtained clearance from the ... with human testing. Portage holds 54% equity interest ...
(Date:8/27/2015)... , August 27, 2015 GlassesOff ... image processing functions in the human vision system, announced today ... point guard Chris Paul to develop a ... who want to improve their real-life on-court performance. ... court, whether it is shooting a ball or blocking a ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet ... a second US laboratory is to open in Manhattan, Kansas in early October, ... and long-term growth of research and development through collaboration with researchers from Kansas ...
(Date:8/26/2015)... 26, 2015  Platform therapeutic company Symic Biomedical, ... a $1.5M Phase II SBIR grant from the ... its therapeutic agent to reduce arteriovenous fistula (AVF) ... stage renal disease (ESRD) patients undergoing hemodialysis. The ... Diabetes and Digestive and Kidney Diseases (NIDDK), will ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
Cached News: